Emeryville, CA, United States
Emeryville, CA, United States

Time filter

Source Type

Patent
NovaBay Pharmaceuticals | Date: 2015-08-20

The present invention relates generally to a magnetic valve system. Embodiments of the present invention provide a system to minimize the potential for mistakenly dispensing one fluid in place of another or desired fluid. More particularly, embodiments of the present invention provide a magnetic valve, where a bias mechanism is provided to bias the magnetic valve into a closed position, whereby a receptacle having a magnet with a magnetic polarity arranged opposite to that of the magnetic valve exerts a force on the magnetic valve sufficient to over come the bias mechanism, and the magnetic valve slides into an open position or state permitting fluid to flow into the receptacle. When the receptacle is removed, the bias mechanism forces the magnetic valve back into the closed position, where no or minimal fluid is permitted to flow.


Dr. Shilpa Rose, an ophthalmologist at Whitten Laser Eye based in Washington, D.C., today is making a public service announcement about the problem of Dry Eye in patients undergoing refractive eye surgery - and how a new product, Avenova® Lid & Lash Hygiene by NovaBay Pharmaceuticals (NYSE MKT: NBY), can help manage this problem. An estimated 4,000,000 Americans every year undergo various types of eye surgery, such as LASIK and cataract surgery. By reshaping the cornea to treat nearsightedness, farsightedness, or astigmatism, LASIK has dramatically improved the vision-and quality of life-for millions of people. With the introduction of multifocal IOL's, cataract surgery patients are now able to retain their full range of vision. Whitten Laser Eye is one of the leading refractive surgical practices nationally, with many high profile patients, including Tiger Woods. Many of the patients coming in for surgery suffer from a condition known as meibomian gland dysfunction (MGD) Dry Eye, especially those who wear contact lenses. That's a problem for eye surgeons. "To get the best possible outcome in surgery, it is imperative that the surface of the eye is in optimal condition, which means first managing the patient's Dry Eye," explains Dr. Rose. "Fortunately, we are finding that we can successfully manage many of the variables of Dry Eye with Avenova®, an innovative daily lid and lash hygiene spray." Meibomian Gland Dysfunction Dry Eye is typically caused or exacerbated by tiny microbes-bacteria and parasitic mites that live on the eyelids. The microbes cause inflammation and block glands near the eye-the meibomian gland-from releasing a natural oil needed for the protective film of tears on the eyes. The microbes also produce lipase, an enzyme that breaks up the crucial oil. "As a result, the eyes lack the normal protective tear film," says Dr. Rose. "Not only can that be a painful and sometimes debilitating condition for patients, it also makes refractive eye surgery more difficult." Avenova directly tackles the major cause of Dry Eye. It is the only lid hygiene product to contain pure 0.01% hypochlorous acid, manufactured by the Neutrox method. Hypochlorous acid is naturally produced in our own white blood cells. In vitro testing shows that hypochlorous acid kills harmful bacteria and mites. It also blocks inflammatory agents released by both the bacteria and the body, and breaks up the enzyme lipase that attacks the tear-protection oil from the meibomian glands. "I love Avenova," says Dr. Rose. "Avenova provides an easy, safe and cost effective regimen to help manage MGD Dry Eye. Dr. Whitten and I now implement Avenova treatment for our refractive and cataract surgeries preoperatively and have been very pleased with the results."


Treating Underlying Conditions like Dry Eye is Essential for Successful LASIK and Cataract Surgery, Top Washington, D.C. Eye Surgeons Say; Avenova Lid & Lash Hygiene is Effective in Managing those Conditions, They Report WASHINGTON, DC / ACCESSWIRE / May 2, 2017 / Dr. Shilpa Rose, an ophthalmologist at Whitten Laser Eye based in Washington, D.C., today is making a public service announcement about the problem of Dry Eye in patients undergoing refractive eye surgery - and how a new product, Avenova® Lid & Lash Hygiene by NovaBay Pharmaceuticals (NYSE MKT: NBY), can help manage this problem. An estimated 4,000,000 Americans every year undergo various types of eye surgery, such as LASIK and cataract surgery. By reshaping the cornea to treat nearsightedness, farsightedness, or astigmatism, LASIK has dramatically improved the vision-and quality of life-for millions of people. With the introduction of multifocal IOL's, cataract surgery patients are now able to retain their full range of vision. Whitten Laser Eye is one of the leading refractive surgical practices nationally, with many high profile patients, including Tiger Woods. Many of the patients coming in for surgery suffer from a condition known as meibomian gland dysfunction (MGD) Dry Eye, especially those who wear contact lenses. That's a problem for eye surgeons. "To get the best possible outcome in surgery, it is imperative that the surface of the eye is in optimal condition, which means first managing the patient's Dry Eye," explains Dr. Rose. "Fortunately, we are finding that we can successfully manage many of the variables of Dry Eye with Avenova®, an innovative daily lid and lash hygiene spray." Meibomian Gland Dysfunction Dry Eye is typically caused or exacerbated by tiny microbes-bacteria and parasitic mites that live on the eyelids. The microbes cause inflammation and block glands near the eye-the meibomian gland-from releasing a natural oil needed for the protective film of tears on the eyes. The microbes also produce lipase, an enzyme that breaks up the crucial oil. "As a result, the eyes lack the normal protective tear film," says Dr. Rose. "Not only can that be a painful and sometimes debilitating condition for patients, it also makes refractive eye surgery more difficult." Avenova directly tackles the major cause of Dry Eye. It is the only lid hygiene product to contain pure 0.01% hypochlorous acid, manufactured by the Neutrox method. Hypochlorous acid is naturally produced in our own white blood cells. In vitro testing shows that hypochlorous acid kills harmful bacteria and mites. It also blocks inflammatory agents released by both the bacteria and the body, and breaks up the enzyme lipase that attacks the tear-protection oil from the meibomian glands. "I love Avenova," says Dr. Rose. "Avenova provides an easy, safe and cost effective regimen to help manage MGD Dry Eye. Dr. Whitten and I now implement Avenova treatment for our refractive and cataract surgeries preoperatively and have been very pleased with the results."


News Article | May 4, 2017
Site: www.businesswire.com

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, announces that it will report 2017 first quarter financial results after market close on Thursday, May 11. Management will hold an investment community conference call that day to discuss financial results and provide a Company update. The live call also will be available at http://novabay.com/investors/events. A replay of the call will be available beginning two hours after its completion through 12:59 p.m. Eastern time June 11, 2017, by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 14535369. The call will also be archived at http://novabay.com/investors/events. About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics® NovaBay Pharmaceuticals is a biopharmaceutical company focusing on the commercialization of prescription Avenova® lid and lash hygiene for the eye care market. Avenova is formulated with Neutrox®, which is cleared by the U.S. Food and Drug Administration (FDA) as a 510(k) medical device. Neutrox is NovaBay’s pure hypochlorous acid. Data from a multicenter clinical study show that Avenova reduced bacterial load, the underlying cause of blepharitis, on ocular skin surface by more than 90%. Laboratory tests show that hypochlorous acid has potent antimicrobial activity in solution yet is non-toxic to mammalian cells and also neutralizes bacterial toxins. Avenova is marketed to optometrists and ophthalmologists throughout the U.S. by NovaBay’s direct medical salesforce. It is accessible from more than 90% of retail pharmacies in the U.S. through agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen. Download our Mobile InvestorApp from the Apple Store or Google Play Like us on Facebook Follow us on Twitter Connect with NovaBay on LinkedIn Join us on Google+ Visit NovaBay's Website


Patent
NovaBay Pharmaceuticals | Date: 2016-05-10

Toxins produced by bacteria promote infection and disease by directly damaging host tissues and by disabling the immune system. In one embodiment, the present application provides methods of treating and prevention further inflammation by inactivating toxins through use positive chlorinated ionic solution and or their derivatives.


Patent
NovaBay Pharmaceuticals | Date: 2012-11-14

This application describes compounds useful as anti-microbial agents, including as antibacterial, disinfectant, antifungal, germicidal or antiviral agents.


Patent
NovaBay Pharmaceuticals | Date: 2014-10-31

The present invention relates generally to systems and methods for cleaning and disinfecting contact lenses. In various respects, the invention is directed to an insulated system that reduces heat loss from catalyzed neutralization of a disinfecting solution resulting in an increased temperature of the disinfection solution during the disinfection process and neutralization of the disinfection solution. The increased temperature increases the kill rate (i.e., better reduction) of microorganisms present on the lenses, and increases the neutralization rate of the disinfection solution. Increase of the kill rate allows better reduction of microorganisms resistant to elimination using previous systems and methods, (e.g., Acanthamoeba cysts), and decreases the amount of time as compared to previous systems and methods necessary to reduce microorganisms to acceptable levels.


Patent
NovaBay Pharmaceuticals | Date: 2016-05-27

Lipases produced by bacteria break down tear lipids and cause or exacerbate discomfort due to meibomian gland dysfunction, blepharitis or dry eye. In one embodiment, the present invention provides methods of treating and prevention further discomfort by inactivating lipases through use chlorinated solution and or their derivatives.


Patent
NovaBay Pharmaceuticals | Date: 2014-09-02

The invention monitors the neutralization process involving hydrogen peroxide solution and a hydrogen peroxide neutralization catalyst and compares measured values with theoretical values. The system monitors the chemical reaction and notifies the user of the neutralization status. In an exemplary embodiment, the initial hydrogen peroxide solution concentration is neutralized with a palladium catalyst after a period of time. A microcontroller analyzes the measurements and displays the neutralization process results using colored LED lights and/or text or images on a LCD display. In one embodiment, an apparatus adapted for use with a cleaning solution used to clean a medical device may include a trigger, a processing device in communication with the trigger, and a display device. The processing device provides a trigger count and the display device communicates with the processing device and displays a message based on the count.


Patent
NovaBay Pharmaceuticals | Date: 2014-04-30

The present invention relates to active bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and antiviral compounds and compositions and to new uses of these compositions in therapy. This specification also describes methods of use for the new compounds and compositions. The specification further describes methods for preparing these compounds.

Loading NovaBay Pharmaceuticals collaborators
Loading NovaBay Pharmaceuticals collaborators